Diagnostic and Prognostic Values of PRAME Immunohistochemistry in Acral Lentiginous Melanoma
Open Access
- 27 May 2026
- journal article
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
Abstract
Background: PReferentially Expressed Antigen in MElanoma (PRAME) was introduced as an ancillary tool for confirming the diagnosis of cutaneous melanoma, including the acral lentiginous melanoma (ALM). However, its standardized cut-off values and prognostic performance remain inconclusive. This study assessed the diagnostic performance of PRAME immunohistochemistry (IHC) in ALM across different thresholds and explored its prognostic associations. Methods: This retrospective cohort study reviewed 90 acral melanocytic lesions, including 60 cases of acral benign nevi and 30 cases of primary ALM. PRAME immunohistochemistry was performed on the biopsy specimens. Sensitivity and specificity were calculated at varying cut-offs. The optimal threshold was applied to link PRAME expression with the outcome and features of ALM. Results: A PRAME staining threshold of 50% (score ≥3) provided the optimum cut-off for differentiating ALM, with a high specificity of 98.3% and sensitivity of 53.3%. Positive PRAME was significantly associated with higher TNM stages (ordinal odds ratio [95% confidence interval], 13.11 [2.55–67.27]) and higher rates of recurrence (hazard ratio, 6.62 [1.42–30.94]) but not with any unfavorable histopathological features or mortality. Conclusion: PRAME can be used as an adjunctive diagnostic tool to differentiate malignant from benign acral melanocytic lesions. It may serve as a prognostic marker for poor ALM outcomes.Keywords
Funding Information
- Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
This publication has 23 references indexed in Scilit:
- PRAME Expression in Recurrent/Persistent Melanocytic NeviThe American Journal of Dermatopathology, 2025
- Clinicopathologic Features of PRAME-Positive Common Melanocytic Nevi: A Case-Control StudyThe American Journal of Dermatopathology, 2025
- The Utility of PRAME and Ki-67 as Prognostic Markers for Cutaneous MelanomaThe American Journal of Dermatopathology, 2024
- Comparison of Melanocyte-Associated Immunohistochemical Markers in Acral Lentiginous Melanoma and Acral Benign NeviThe American Journal of Dermatopathology, 2023
- Immunohistochemistry for PRAME in DermatopathologyThe American Journal of Dermatopathology, 2023
- Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 casesPathology - Research and Practice, 2023
- Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral neviHuman Pathology, 2022
- Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic NeoplasmsThe American Journal of Dermatopathology, 2021
- Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 updateInternational Journal of Clinical Oncology, 2008
- Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory ReceptorImmunity, 1997